Video
Video report: Norursodeoxycholic acid and atherosclerosis
Summary:
Bile acids formed the focus of the 194th international Falk Symposium, which took place in Freiburg at the beginning of October. Since being identified as important hormones for regulating metabolism, bile acids have been examined for their therapeutic potential. Professor Dr. Michael Trauner from the University Hospital of Vienna presented exciting findings on how norursodeoxycholic acid affects the development of atherosclerosis. Norursodeoxycholic acid was examined using an established mouse model for atherosclerosis (apolipoprotein E-deficient mice). When they consume typical Western diets, these mice spontaneously develop atherosclerotic lesions in their entire network of arteries, which has a similar structure in humans. Administering norursodeoxycholic acid reduced the development of atherosclerosis and non-alcoholic fatty liver disease. With regard to lipid metabolism, administering norursodeoxycholic acid was also shown to increase levels of HDL cholesterol. This suggests that hydrophilic bile acid may not only represent a treatment option for cholestatic liver diseases but, at least in the mouse model, can also successfully reduce atherosclerosis and fatty liver disease. To date, norursodeoxycholic acid has been shown experimentally to have the following effects on non-alcoholic fatty liver disease: improvements in fatty liver disease, hepatic inflammation and atherosclerosis.
Video-Report presented by: Professor Dr. Michael Trauner, University Hospital of Vienna at the 194th international Falk Symposium „XXIII. International Bile Acid Meeting: Bile Acids as Signal Integrators and Metabolic Modulators“, October 8th – 9th 2014, Freiburg i. Br.
© Falk Foundation e.V., Freiburg. All rights reserved.
Please switch on your loudspeakers!
Link to Falk Mediacenter:
http://media.falkfoundation.de/index.php?id=110&L=1
Link to the video directly:
http://media.drfalkpharma.de/fileadmin/media/150204_Trauner_ENG_V6_mittel.mp4
Preview images:
180 x 109 pixels
http://www.drfalkpharma.de/fileadmin/media/Video/FS194_Trauner_180P.jpg
580 x 350 pixels
http://www.drfalkpharma.de/fileadmin/media/Video/FS194_Trauner_580.jpg
Bowel
Text:
Lopez A et al, Clin Gastroenterol Hepatol. 2014;12(8):1324–9
Past exposure to thiopurines increases the risk of myeloid disorders 7-fold among patients with inflammatory bowel disease.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20366#28094
Text:
Miehlke S et al, Gastroenterology. 2014;146(5):1222–30
Oral budesonide (9 mg once daily) is effective and safe for short-term treatment of collagenous colitis.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20366#c28095
Text:
Cremon C et al, Gastroenterology. 2014;147(1):69–77
Salmonella-induced gastroenteritis during childhood (but not adulthood) is a risk factor for irritable bowel syndrome.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20366#c28096
Liver
Biliary Tracts
Text:
Greenup AJ et al, J Hepatol. 2014;61(3):502–7
Tenofovir prevents perinatal transmission of the hepatitis B virus.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20366#c28097
Text:
Ferenci P et al, N Engl J Med. 2014;370(21):1983–92
Poordad F et al, N Engl J Med. 2014;370(21):1973–82
Andreone P et al, Gastroenterology. 2014;147(2):359–65
The interferon-free combination therapy of chronic hepatitis C genotype 1 with paritaprevir/ritonavir + ombitasvir + dasabuvir is highly effective in 1. Previously untreated patients (Ferenci et al.) 2. Patients with liver cirrhosis (Poordad et al.) 3. Previously treated patients (Andreone et al.).
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20366#c28098
Text:
Lunia MK et al, Clin Gastroenterol Hepatol. 2014;12(6):1003–8
Probiotics were found to be effective in preventing hepatic encephalopathy in patients with cirrhosis.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20366#c28099
Oesophagus
Stomach
Duodenum
Text:
Singh S et al, Gastrointest Endosc. 2014;79(6):897–909
The incidence of esophageal adenocarcinoma among patients with Barrett’s esophagus and low-grade dysplasia is 0.54% annually.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20366#c28100
Text:
Singh S et al, Gut. 2014;63(8):1229–37
The use of proton-pump inhibitors is associated with a decreased risk of esophageal adenocarcinoma and/or Barrett’s esophagus with high-grade dysplasia in patients with Barrett’s esophagus.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20366#c28101
Text:
Arias Á et al, Gastroenterology. 2014;146(7):1639–48
Dietary interventions are effective in producing histologic remission in patients with eosinophilic esophagitis. Elemental diets and 6-food elimination diets were the most effective.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20366#c28102
Pancreas
http://www.drfalkpharma.de/fileadmin/media/logos_falk/abstracts/Panc-Logo-FGR.gif
Text:
Galassi E et al, Pancreas. 2014;43(6):874–8
Benign pancreatic hyperenzymemia is a not so rare condition.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=20366#c28103